JP2018508556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508556A5 JP2018508556A5 JP2017549188A JP2017549188A JP2018508556A5 JP 2018508556 A5 JP2018508556 A5 JP 2018508556A5 JP 2017549188 A JP2017549188 A JP 2017549188A JP 2017549188 A JP2017549188 A JP 2017549188A JP 2018508556 A5 JP2018508556 A5 JP 2018508556A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- medicament according
- compound
- medicament
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024891 symptom Diseases 0.000 claims description 4
- 230000001457 vasomotor Effects 0.000 claims description 4
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000003839 salts Chemical group 0.000 claims 5
- 102100028874 Sodium-dependent serotonin transporter Human genes 0.000 claims 4
- 101710114597 Sodium-dependent serotonin transporter Proteins 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 206010060800 Hot flush Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000027559 Appetite disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000033830 Hot Flashes Diseases 0.000 claims 1
- 241000023320 Luma <angiosperm> Species 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 102100033929 Sodium-dependent noradrenaline transporter Human genes 0.000 claims 1
- -1 alkyl luma Chemical compound 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562135915P | 2015-03-20 | 2015-03-20 | |
| US62/135,915 | 2015-03-20 | ||
| PCT/US2016/023198 WO2016154027A1 (en) | 2015-03-20 | 2016-03-18 | Organic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508556A JP2018508556A (ja) | 2018-03-29 |
| JP2018508556A5 true JP2018508556A5 (enExample) | 2019-04-18 |
| JP6726200B2 JP6726200B2 (ja) | 2020-07-22 |
Family
ID=56977765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549188A Active JP6726200B2 (ja) | 2015-03-20 | 2016-03-18 | 有機化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10188758B2 (enExample) |
| EP (1) | EP3270920B1 (enExample) |
| JP (1) | JP6726200B2 (enExample) |
| KR (1) | KR20170129906A (enExample) |
| CN (1) | CN107405339A (enExample) |
| AU (1) | AU2016235483A1 (enExample) |
| BR (1) | BR112017020135A2 (enExample) |
| CA (1) | CA2978668A1 (enExample) |
| ES (1) | ES2819833T3 (enExample) |
| IL (1) | IL254320A0 (enExample) |
| MX (1) | MX2017012022A (enExample) |
| RU (1) | RU2017134796A (enExample) |
| WO (1) | WO2016154027A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3339304A1 (en) | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Quinoline and isoquinoline derivatives for treating pain and pain related conditions |
| EP3339307A1 (en) * | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Nitrogen containing bicyclic derivatives for treating pain and pain related conditions |
| CN113195489A (zh) * | 2018-11-02 | 2021-07-30 | 埃斯特韦制药股份公司 | 用于治疗疼痛和疼痛相关病症的新的烷氧基氨基吡啶衍生物 |
| EP3873902A1 (en) * | 2018-11-02 | 2021-09-08 | Esteve Pharmaceuticals, S.A. | New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU709704B2 (en) * | 1995-07-24 | 1999-09-02 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
| AU2003287023A1 (en) * | 2002-11-05 | 2004-06-03 | Eli Lilly And Company | 3-aryloxy/ thio-2, 3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| EA200601798A1 (ru) * | 2004-04-30 | 2007-04-27 | Уорнер-Ламберт Компани Ллс | Замещенные соединения морфолина для лечения расстройств центральной нервной системы |
| WO2007010082A1 (en) * | 2005-07-15 | 2007-01-25 | Fermion Oy | Process for preparing a 3-aryloxy-3-arylpropylamine |
| CA2661187A1 (en) * | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Piperidine derivatives |
| EP2161998B1 (en) * | 2007-06-04 | 2015-09-02 | Intra-Cellular Therapies, Inc. | Pyridine derivatives as NET/SERT modulators |
| WO2010120910A1 (en) * | 2009-04-15 | 2010-10-21 | Theravance, Inc. | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| US9352218B2 (en) | 2009-04-21 | 2016-05-31 | Nintendo Co., Ltd. | Game apparatus and computer-readable storage medium |
-
2016
- 2016-03-18 EP EP16769428.0A patent/EP3270920B1/en active Active
- 2016-03-18 WO PCT/US2016/023198 patent/WO2016154027A1/en not_active Ceased
- 2016-03-18 CA CA2978668A patent/CA2978668A1/en not_active Abandoned
- 2016-03-18 BR BR112017020135A patent/BR112017020135A2/pt not_active Application Discontinuation
- 2016-03-18 KR KR1020177030305A patent/KR20170129906A/ko not_active Withdrawn
- 2016-03-18 ES ES16769428T patent/ES2819833T3/es active Active
- 2016-03-18 AU AU2016235483A patent/AU2016235483A1/en not_active Abandoned
- 2016-03-18 JP JP2017549188A patent/JP6726200B2/ja active Active
- 2016-03-18 CN CN201680014968.7A patent/CN107405339A/zh active Pending
- 2016-03-18 RU RU2017134796A patent/RU2017134796A/ru not_active Application Discontinuation
- 2016-03-18 US US15/560,107 patent/US10188758B2/en active Active
- 2016-03-18 MX MX2017012022A patent/MX2017012022A/es unknown
-
2017
- 2017-09-04 IL IL254320A patent/IL254320A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508556A5 (enExample) | ||
| RU2007139541A (ru) | Производные хромана и хромена и их применение | |
| JP2020528431A5 (enExample) | ||
| JP2017509686A5 (enExample) | ||
| JP2009527462A5 (enExample) | ||
| JP2008533007A5 (enExample) | ||
| JP2013544850A5 (enExample) | ||
| RU2016143357A (ru) | Органические соединения | |
| RU2018130727A (ru) | Органические соединения | |
| CL2018000036A1 (es) | Derivados etinilo | |
| JP2012521429A5 (enExample) | ||
| JP2016506935A5 (enExample) | ||
| MX2019014368A (es) | Agentes de imagenologia nuevos para tomografia de emision de positrones (pet) sustituidos con deuterio y su aplicacion farmacologica. | |
| JP2016506933A5 (enExample) | ||
| CN109982699A (zh) | 一种mor激动剂与kor激动剂的药物组合物及其用途 | |
| JP2018505204A5 (enExample) | ||
| JP2012519182A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2002515435A (ja) | 鬱病処置のための組合せ治療 | |
| JP2019516739A5 (enExample) | ||
| JP2010526827A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| RU2016136193A (ru) | Аминокарбонилкарбаматные соединения |